Ying Mm Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ying Mm Huang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Guozheng Qin
The First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China
1 shared publication - Hongying Li
First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, China
1 shared publication - Lei Xu
First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, China
1 shared publication - Menghua Shi
Department of Anorectal Surgery, The First Affiliated Hospital of Henan University of CM, Zhengzhou, China
1 shared publication - Yanfang Mm Yang
First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, China
1 shared publication - Zhaodi Mm Hu
First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, China
1 shared publication
Latest Publications
- Open Access
- 13 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (37) , e39558
Bixie Fenqing decoction in the treatment of chronic prostatitis: A systematic review and meta-analysis
Background: Traditional Chinese medicine (TCM) posits that chronic prostatitis is associated with the accumulation of damp-heat pathogenic factors in the lower jiao. The Bixie Fenqing decoction (BFD) eliminates damp-heat pathogenic factors in the body, thereby alleviating inflammation and improving symptoms. Methods: Databases such as CNKI, WanFang, VIP, CBM, ClinicalKey, PubMed, Embase, and the Cochrane Library were searched. The search time ranged from the establishment of the database until March 30, 2024. RCTs that used BFD for chronic prostatitis were screened. The methodological quality of the studies was evaluated using the Cochrane Scoring System. Meta-analysis of outcome indicators was performed using RevMan 5.4 software, and Egger analysis of publication bias for the primary outcome indicators was conducted using Stata 16 software. Results: This analysis included 1104 patients. Meta-analysis showed that BFD significantly improved clinical efficacy in patients with chronic prostatitis, with a total effective rate (RR = 1.20, 95% CI: 1.13 to 1.26, P < .00001) and cure rate (RR = 1.52, 95% CI: 1.24 to 1.86, P < .00001). It significantly reduced the NIH-CPSI (National Institutes of Health-Chronic Prostatitis Symptom Index) scores, levels of inflammatory factors, white blood cell counts, and TCM syndrome scores in patients with chronic prostatitis. Specifically, the NIH-CPSI total scores (MD = −4.41, 95% CI: −5.27 to −3.55, P < .00001), NIH-CPSI pain scores (MD = −2.08, 95% CI: −2.93 to −1.23, P < .00001), NIH-CPSI urinary symptom scores (MD = −1.13, 95% CI: −1.69 to −0.57, P < .0001), NIH-CPSI quality of life scores (MD = −1.25, 95% CI: −1.76 to −0.75, P < .00001), levels of inflammatory factors TNF-α (MD = −11.18, 95% CI: −13.84 to −8.53, P < .00001) and IL-10 (MD = −20.60, 95% CI: −26.82 to −14.37, P < .00001) in prostatic fluid, white blood cell counts in prostatic fluid (MD = −2.91, 95% CI: −5.46 to −0.36, P = .03), and TCM syndrome scores (MD = −7.01, 95% CI: −8.13 to −5.90, P < .00001) were all significantly improved. Conclusion: BFD has a definite effect on the treatment of chronic prostatitis.
- 13 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (37) , e39558
Open AccessBixie Fenqing decoction in the treatment of chronic prostatitis: A systematic review and meta-analysis
Background: Traditional Chinese medicine (TCM) posits that chronic prostatitis is associated with the accumulation of damp-heat pathogenic factors in the lower jiao. The Bixie Fenqing decoction (BFD) eliminates damp-heat pathogenic factors in the body, thereby alleviating inflammation and improving symptoms. Methods: Databases such as CNKI, WanFang, VIP, CBM, ClinicalKey, PubMed, Embase, and the Cochrane Library were searched. The search time ranged from the establishment of the database until March 30, 2024. RCTs that used BFD for chronic prostatitis were screened. The methodological quality of the studies was evaluated using the Cochrane Scoring System. Meta-analysis of outcome indicators was performed using RevMan 5.4 software, and Egger analysis of publication bias for the primary outcome indicators was conducted using Stata 16 software. Results: This analysis included 1104 patients. Meta-analysis showed that BFD significantly improved clinical efficacy in patients with chronic prostatitis, with a total effective rate (RR = 1.20, 95% CI: 1.13 to 1.26, P < .00001) and cure rate (RR = 1.52, 95% CI: 1.24 to 1.86, P < .00001). It significantly reduced the NIH-CPSI (National Institutes of Health-Chronic Prostatitis Symptom Index) scores, levels of inflammatory factors, white blood cell counts, and TCM syndrome scores in patients with chronic prostatitis. Specifically, the NIH-CPSI total scores (MD = −4.41, 95% CI: −5.27 to −3.55, P < .00001), NIH-CPSI pain scores (MD = −2.08, 95% CI: −2.93 to −1.23, P < .00001), NIH-CPSI urinary symptom scores (MD = −1.13, 95% CI: −1.69 to −0.57, P < .0001), NIH-CPSI quality of life scores (MD = −1.25, 95% CI: −1.76 to −0.75, P < .00001), levels of inflammatory factors TNF-α (MD = −11.18, 95% CI: −13.84 to −8.53, P < .00001) and IL-10 (MD = −20.60, 95% CI: −26.82 to −14.37, P < .00001) in prostatic fluid, white blood cell counts in prostatic fluid (MD = −2.91, 95% CI: −5.46 to −0.36, P = .03), and TCM syndrome scores (MD = −7.01, 95% CI: −8.13 to −5.90, P < .00001) were all significantly improved. Conclusion: BFD has a definite effect on the treatment of chronic prostatitis.